Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The management of high-risk ALL

Arnon Nagler • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, talks on the management of high-risk acute lymphoblastic leukemia (ALL), commenting on the use of bispecific T-cell engagers (BiTE) like blinatumomab and antibody-drug conjugates (ADCs) like inotuzumab ozogamicin, and discussing the role of allogeneic transplantation and CAR-T therapy in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Arnon Nagler

Molecular profiling and MRD are reshaping transplant decision-making in AML
3:19
Molecular profiling and MRD are reshaping transplant decision-making in AML
Arnon Nagler • 15 Jun 2026
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
3:26
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
Arnon Nagler • 15 Jun 2026
Targeted therapies and immunotherapy are redefining transplantation in AML
3:18
Targeted therapies and immunotherapy are redefining transplantation in AML
Arnon Nagler • 15 Jun 2026
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
2:40
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
Arnon Nagler • 15 Jun 2026

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals